Is trospium chloride an effective and safe treatment for overactive bladder syndrome?
Christopher K Payne
Correspondence Department of Urology, Stanford Health Services, 300 Pasteur Drive, S-287, Stanford, CA 94305-5118, USA
Email cpayne@stanford.edu
This article has no abstract so we have provided the first paragraph of the full text.
This article introduces a new ANTIMUSCARINIC agent, recently approved by the FDA for treatment of OAB. The study design is of high quality and similar to that of other recent randomized controlled trials in OAB. It should be noted that this double-blind, placebo-controlled trial is actually a study of urge incontinence, as a minimum of seven incontinence episodes per week was a selection criterion.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.